Supply Chain

Issues include apparently diverted opioids and mislabeled medications

As the definition of ‘targeted’ therapies—especially in oncology—and as a component of companion diagnostics, biomarkers are creating opportunities in drug research and commercialization

30-day deadline for making an application to participate; in the EU, the FMD program is progressing

A marketing challenge: how to make more adults aware of anti-bacterial booster shots

Expansions in the capability of supply chain participants to manage temperature-controlled pharmaceuticals

Even as the science behind the new therapies is getting established, payers are preparing for their extraordinary cost

Broader capabilities for refrigerated or cryogenic transport of cellular materials

Field trial results to be unveiled at upcoming meeting

Partnership with Dacos A/S; FDA will look closer at cellular and genetic therapies

List includes 25 orphan drugs; there were also seven additional biosimilars

Flu activity is “elevated” nationally; Walgreens sees a hotspot in Nebraska

Nearly a million US citizens live with HIV, a virus that still lacks a curative therapy

Cellular and genetic therapies (CGTs) developers are struggling to build capacity

Oncology represents half of the dollar volume of HDA-member sales

Action consolidates leading courier companies with larger freight forwarders

Sales volume handled by primary wholesaler/distributors seems to be declining

The carbon footprint of shipping alternatives is also becoming a competitive issue

New Cardinal Health survey sees the profession adjusting to value-based care

More-complete information is desirable on some applications

AI tools enable Verantos to provide more accurate RWE data for FDA approvals

Rockford, IL, site will get dedicated refrigerated packaging capacity

Better data-sharing for cellular and genetic therapies is the goal

Collaboration with CSP Technologies brings CSP Activ-Blister solutions to blister packaging

The widening scope of RWE data available from patients is changing both clinical and post-approval practices for drug development